

Invega Sustenna® Review

1. You are preparing to administer Invega Sustenna® to a patient who weighs 146 pounds. What size needle will you use?

I will use a 1 in. 23G needle.

2. Name the most common side effects a patient may experience when taking Invega Sustenna®.

The most common side effects are injection site reactions, somnolence/sedation, dizziness, akathisia, and extrapyramidal disorder.

3. What black box warning is associated with this medication?

Increased mortality in elderly patients with dementia-related psychosis.

- 4. What are the standard *recommended* Day 1 and Day 8 initiation dosages for a person with schizophrenia?

234 mg for Day 1 and 156 mg for Day 8.

- 5. What is the standard *recommended* maintenance dosage for a patient with schizophrenia?

117 mg monthly

6. What is the correct location for administration of the Day 1 and Day 8 initiation doses?

The deltoid only for both doses.

7. What are the *recommended* Day 1 and Day 8 initiation dosages for a person with a creatinine clearance of 65 mL/min?

Day 1: 156 mg, Day 8: 117 mg

8. What would the *recommended* maintenance dosage be for a patient with mild renal impairment?

The recommended monthly maintenance dose would be 78mg.

9. What is the rationale for a trial of oral paliperidone or oral or injectable risperidone before placing a patient on Invega Sustenna®?

Paliperidone is the major active metabolite of risperidone, so tolerability should be tested before starting Invega.

10. Name three practices when preparing an intramuscular injection that ensure aseptic technique is maintained throughout the procedure.

Hand hygiene, cleaning injection site with alcohol, and maintaining sterility of the needle.

11. Explain the rationale for obtaining consent for this psychoactive medication prior to preparing the medication for administration.

It comes with significant risks and effects so the patient has the right to get a full understanding of this med if it is the treatment they desired.